Fig. 3: VEGFR-3 blocking treatment increases CD4+ Tnaive in the dLN during acute inflammation and resolution, and decreases CCL21 and other chemokines in the lungs during acute inflammation. | Mucosal Immunology

Fig. 3: VEGFR-3 blocking treatment increases CD4+ Tnaive in the dLN during acute inflammation and resolution, and decreases CCL21 and other chemokines in the lungs during acute inflammation.

From: Pro-lymphangiogenic VEGFR-3 signaling modulates memory T cell responses in allergic airway inflammation

Fig. 3

Mice were challenged as described in Fig. 2. CD4+ T-cell subsets including CD4+ Tnaive, TReg, and Th2 cells in the dLN at a day 13 and day 31. Levels of the CCR7 chemokine, CCL21, in lungs and dLN as determined by b immunofluorescence staining, possible since CCL21 both sticks to extracellular matrix and cytoplasm, (scale bar indicates 400 µm) and c ELISA. d Luminex assay on lung lysates to assess chemokine levels including CXCL2, CCL5, CCL7, CXCL10, CCL11, CCL12, CCL2, CXCL13, CCL3, and CXCL12 at day 13. Boxes represent median (central bar) with range from 25th to 75th percentile, and whiskers represent min to max value. Data are representative of n ≥ 4 inflamed mice and statistics (two-tailed Student’s t test) were performed in GraphPad Prism. #0.05 < p ≤ 0.15, *p < 0.05, **p ≤ 0.01, ***p < 0.001.

Back to article page